Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of ...

In its yearly survey of international clinicians and patients, Philips illustrated significant gaps in people’s trust when it ...

Biohaven is giving investors whiplash. Forty-eight hours after saying its filing was on track, the biopharma revealed the FDA ...

WASHINGTON — FDA Commissioner Martin Makary offered more details into the agency’s recently announced plans to place ...

The Garden State is looking to grow into the next big biotech hub. | The Garden State is looking to grow into the next big ...

Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

Medtech association AdvaMed went to Capitol Hill today to make the case that the medical device industry should be exempt ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) ...

Acelyrin’s shareholders have decided to power ahead with a planned merger with immune-mediated disease specialist Alumis, ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

Allogene Therapeutics is cutting back to stretch its cash runway into the second half of 2027, laying off 28% of its ...